Millennium Management LLC grew its holdings in shares of MEDNAX Inc (NYSE:MD) by 381.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 340,081 shares of the company’s stock after purchasing an additional 269,457 shares during the quarter. Millennium Management LLC owned about 0.40% of MEDNAX worth $7,692,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the company. Swiss National Bank raised its position in shares of MEDNAX by 0.4% in the second quarter. Swiss National Bank now owns 163,500 shares of the company’s stock valued at $4,125,000 after purchasing an additional 600 shares during the period. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of MEDNAX by 56.2% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 1,773 shares of the company’s stock worth $40,000 after buying an additional 638 shares during the period. Robecosam AG boosted its holdings in shares of MEDNAX by 4.0% during the 2nd quarter. Robecosam AG now owns 17,100 shares of the company’s stock worth $421,000 after buying an additional 665 shares during the period. Parallel Advisors LLC grew its stake in MEDNAX by 78.4% in the 3rd quarter. Parallel Advisors LLC now owns 1,993 shares of the company’s stock valued at $45,000 after buying an additional 876 shares during the last quarter. Finally, Sage Capital Advisors llc grew its stake in MEDNAX by 1.7% in the 3rd quarter. Sage Capital Advisors llc now owns 55,818 shares of the company’s stock valued at $1,263,000 after buying an additional 935 shares during the last quarter. Institutional investors and hedge funds own 92.81% of the company’s stock.
Shares of MEDNAX stock opened at $25.37 on Tuesday. MEDNAX Inc has a 52-week low of $19.93 and a 52-week high of $39.96. The firm has a market capitalization of $2.18 billion, a PE ratio of 7.23, a price-to-earnings-growth ratio of 1.00 and a beta of 0.75. The company has a debt-to-equity ratio of 1.35, a current ratio of 1.93 and a quick ratio of 1.93. The company’s fifty day moving average price is $25.30 and its two-hundred day moving average price is $23.90.
MD has been the subject of a number of research analyst reports. Credit Suisse Group cut their target price on shares of MEDNAX from $30.00 to $28.00 and set an “outperform” rating for the company in a research report on Tuesday, August 27th. UBS Group decreased their price target on shares of MEDNAX from $19.00 to $18.00 and set a “sell” rating for the company in a report on Friday, October 18th. Mizuho set a $25.00 price target on MEDNAX and gave the company a “hold” rating in a research report on Friday, November 1st. Bank of America lowered MEDNAX from a “neutral” rating to an “underperform” rating and set a $19.00 price objective on the stock. in a research note on Friday, September 6th. Finally, TheStreet cut MEDNAX from a “c-” rating to a “d” rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the stock. MEDNAX presently has an average rating of “Hold” and a consensus target price of $26.56.
In other news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the company’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $22.88, for a total value of $114,400.00. Following the sale, the director now owns 10,821 shares of the company’s stock, valued at approximately $247,584.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 3.40% of the stock is owned by insiders.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
See Also: Return on Investment (ROI)
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.